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0959-8049/ª 2017 Elsevier Ltd. All righAbstract An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treat-
ment of nonesmall cell lung cancer (NSCLC). QT prolongation is one of the known, but rela-
tively rare, adverse events of several TKIs (e.g. osimertinib, crizotinib, ceritinib). Screening for
QT prolongation in (high risk) patients is advised for these TKIs. When a QT prolongation de-
velops, the physician is challenged with the question whether to (permanently) discontinue the
TKI. In this perspective, we report on a patient who developed a grade III QT prolongation dur-
ing osimertinib (a third-generation epidermal growth factor receptor [EGFR]-TKI) treatment.
On discontinuation of osimertinib, she developed a symptomatic disease flare, not responding to
subsequent systemic treatment. The main aim of this perspective is to describe the management
of QT prolongation in stage IV EGFR driver mutation NSCLC patients. We also discuss the
ethical question of how to weigh the risk of a disease flare due to therapy cessation against
the risk of sudden cardiac death. A family history of sudden death and a prolonged QT interval
might indicate a familiar long QT syndrome. We have summarised the current monitoring
advice for TKIs used in the treatment of lung cancer and the most common drugeTKI interac-
tions to consider and to optimise TKI treatment in lung cancer patients.
ª 2017 Elsevier Ltd. All rights reserved.433875051.
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M. Schiefer et al. / European Journal of Cancer 91 (2018) 92e98 931. IntroductionMore and more targetable molecular drivers of non-
small cell lung cancer (NSCLC) are being discovered [1].
The targeted agents for these driver mutations are often
tyrosine kinase inhibitors (TKIs). The European Medi-
cines Agency (EMA)- and US Food and Drug Admin-
istration (FDA)eapproved TKIs for activating
epidermal growth factor receptor (EGFR) mutations
include erlotinib, gefitinib, afatinib and osimertinib.
Examples of TKIs approved for anaplastic lymphomaFig. 1. Primary tumour in the left lower lobe before, during and aft
primary tumour in the left lower lobe, adjacent to a pleural thickenin
mertinib therapy. (B) Day 32 of osimertinib therapy, partial response.
Day 301, slow progression. (F) Day 350, rapid progression after cessakinase rearrangements are crizotinib, ceritinib and
alectinib and for ROS1 translocations, crizotinib is
approved [1]. EGFR mutations are found in approxi-
mately 10e15% of Caucasian patients with stage IV
non-squamous NSCLC [2], and this percentage in-
creases to more than 60% in non-smoking Asian females
[3]. An activating EGFR mutation is predictive for
response to EGFR-TKI [4]. For example, osimertinib is
a third-generation EGFR-TKI and EMA approved for
EGFR-mutated patients with a T790M mutation.
Recently, results of the first line randomised phase IIIer osimertinib therapy. Consecutive CT scans demonstrating the
g and calcification caused by previous empyema. (A) Before osi-
(C) Day 183, stable situation. (D) Day 241, slow progression. (E)
tion of osimertinib. CT, computed tomography.
M. Schiefer et al. / European Journal of Cancer 91 (2018) 92e9894FLAURA trial were reported, and it was shown that
osimertinib had a superior progression free survival
(PFS) compared with gefitinib [5]. For osimertinib, most
common adverse events (almost all grade I or II) are
diarrhoea (41%), rash (34%), dry skin (23%) and paro-
nychia (22%). Although not frequent, QT prolongation
is one of the known adverse events, and this occurs in
approximately 4% of patients (almost all patients grade
I or II) [6]. For several other TKIs, QT prolongation has
been described [7e10]. For a grade III QT prolongation,
it is advised to temporarily discontinue the causative
agent as there is an increased risk of sudden cardiac
death due to ventricular tachycardia and torsade de
pointes [11]. However, discontinuation of a TKI can
result in a rapid symptomatic disease flare [12]. In the
case reported below, we discuss that a disease flare due
to therapy cessation should be weighed against the risk
of sudden cardiac death. Furthermore, we provide rec-
ommendations for QT management in a patient treated
with a TKI. In a broader perspective, we summarise the
current monitoring advice for TKIs (almost) approved
for the treatment of lung cancer and the most common
drugeTKI interactions to consider and to optimise TKI
treatment of lung cancer patients.
1.1. Case report
A 62-year-old female known with stage IV pulmonary
adenocarcinoma with an EGFR exon 19 deletion was
treated with fourth line osimertinib 80 mg once daily.
This was well tolerated and resulted in a rapid clinical
and radiological response. After 9 months, a very slow
asymptomatic progression was observed (Fig. 1); osi-
mertinib was continued because of persisting clinical
benefit. Regular (2 weekly) electrocardiograms (ECGs)Fig. 2. QT interval during osimertinib therapy. (A) Graphic present
osimertinib therapy, which was discontinued at day 302. (B) Electrocard
QTc of 444 ms. (C) ECG at day 302 of osimertinib therapy, demonstwere performed for the first 2 months, thereafter
monthly. These ECGs showed no abnormalities. How-
ever, after 11 months, there was a sudden grade III QT
prolongation (560 ms) (Fig. 2). Electrolytes were
normal; no other QT-prolonging drugs were used. Osi-
mertinib was discontinued, and on advice of the cardi-
ologist, a detailed family history was obtained. A
brother and uncle had sudden cardiac deaths. Because
of the family history, the patient was referred for genetic
counselling for a workup of familial QT prolongation.
Genetic counselling showed no specific mutations
related to the long QT syndrome (no pathogenic muta-
tions in KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2,
KCNJ8, CAV3, KCNJ2 and exon 8 of the CACNA1C
gene) [13,14]. Within 5 days, the QT interval normalised,
and osimertinib was not reintroduced because of the
already occurring slow progressive disease. A new
tumour biopsy was performed directly after dis-
continuing osimertinib. Within 2 weeks of discontinuing
osimertinib, while awaiting biopsy results, a rapid
symptomatic disease progression occurred, not
responding to fifth line pemetrexed monotherapy. Bi-
opsy results became available during pemetrexed treat-
ment but revealed no druggable target and no T790M.
The patient died from symptomatic brain metastasis 2
months after discontinuation of osimertinib.
1.2. Discussion: monitoring of TKI treatment
For several TKIs, grade III or higher QT prolongation
has been described (e.g. osimertinib: 1%, dacomitinib:
1%, crizotinib: 3%, ceritinib: 3e6%) [7e10]. Animal
models suggest that this is caused by inhibition of PI3K
signalling [15]. QT prolongation has been reported in
4% of patients receiving osimertinib and was classified aation of the development of corrected QT time during and after
iogram (ECG) at the start of osimertinib therapy, demonstrating a
rating a QTc of 560 ms.
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M. Schiefer et al. / European Journal of Cancer 91 (2018) 92e98 95grade III adverse event in 1%. Although the QT pro-
longation is rare, for osimertinib, it is advised to regu-
larly perform an ECG in patients at risk for QT
prolongation [11]. For crizotinib and ceritinib, it is
advised to perform baseline ECGs in all patients and
regular ECGs at least in patients at risk for QT pro-
longation [16,17]. As the TKIs used in the treatment of
driver mutated NSCLC differ in their adverse event
profile, monitoring of patients should be tailored ac-
cording to the prescribed TKI. Furthermore, interaction
with other drugs can cause an increase or decrease in the
plasma concentration of the TKI, resulting in a higher
chance of adverse events or in possible undertreatment
of the patient. Monitoring advice is summarised in
Table 1, and possible drugeTKI interactions with the
resulting effects on the TKI are presented in Table 2.
A prolonged QT interval can lead to ventricular
tachycardia and torsade de pointes with potentially fatal
outcome. It can present as a congenital ’long QT syn-
drome’ and can be provoked by conditions such as
bradycardia or hypokalemia or exposure to certain
drugs. In general, a QT prolongation beyond 500 ms
should prompt cessation of QT-prolonging drugs to
prevent sudden cardiac death as the relative risk of a
cardiac death is more than 2.5 times that of a person
without QT prolongation [14,18]. Predisposing factors
for QT prolongation and their risk management are
summarised in Table 3.
In our case, the risk of fatal arrhythmia due to QT
prolongation occurred in the context of a stage IV
EGFR-mutated pulmonary adenocarcinoma that was
treated with an EGFR-TKI. Disease flare after TKI
discontinuation has been described and occurred after a
median of 8 days [12]. This unfavourable prognostic
consequence of therapy cessation should be weighed
against the risk of sudden cardiac death. An ethical
question is whether a risk of iatrogenic death is
acceptable in palliative oncologic therapy. In case of
therapy continuation, preventive measures to limit the
risk of cardiac arrhythmias consist of early patient
reporting of palpitations and (near) syncope, early
recognition and treatment of hypokalemia, beta-blocker
therapy and avoidance of concomitant QT-prolonging
or interacting drugs (Table 3) [13,14]. Furthermore,
attention should be paid to the family history as a
prolonged QT interval might indicate a familial long QT
syndrome [13,14]. When there is an indication for a fa-
milial long-QT syndrome, first degree family members
with a (suspicion of) a long-QT syndrome are eligible for
a periodical cardiology evaluation [19]. In general, one
should be aware of the monitoring advice for TKI use
and possible drugeTKI interactions to optimise the
TKI treatment of lung cancer patients.
At this point, we do not know if dose reduction is
associated with a decreased risk of QT prolongation or
if QT prolongation would recur or not with the intro-
duction of a lower dose. However, as our patient already
Table 2
Summary of important drug interactions per TKI.
Type of drug CYP3A4
inhibitorsb
CYP3A4
inducersc
CYP1A2
inhibitorsd
P-gp
inhibitorse
P-gp
inducersf
P-gpe
dependent
drugsg
BCRP-
dependent
drugh
CYP3A-
dependent
drugsi
CYP2C9-
dependent
drugsj
CYP2B6-
dependent
drugsk
CYP2D6-
dependent
drugsl
QT-
prolonging
drugsm
Gastrointestinal
toxic drugs
Hepatotoxic
drugs
Gastric pHe
modifying
agents
Coumarins
(INR increase)
Statins
(myopathy
risk)
Oral
contraception
unsafe
Gefitinib (Iressa) [20] x x x x x x
Erlotinib (Tarceva) [21] x x x x x x x
Afatinib (Giotrif) [22] x x x
Dacomitiniba
(PF-00299804) [23]
x x x x
Osimertinib (Tagrisso) [11] x x x x
Crizotinib (Xalkori) [16] x x x x x x x x x
Ceritinib (Zykadia) [17] x x x x x x x x
Alectinib (Alecensa) [24] x x x
Brigatinib (Alunbrig) [25] x x x
Lorlatiniba (PF-6463922)
[26]
x x x Xn x x x
FDA, US Food and Drug Administration; TKI, tyrosine kinase inhibitor; EMA, European Medicines Agency.
a
Not yet FDA or EMA approved.
b
CYP3A4-inhibiting drugs increase TKI concentration, i.e. grapefruit juice, azoles, erythromycin, clarithromycin, boceprevir and HIV protease inhibitors.
c
CYP3A-inducing drugs decrease TKI concentration, i.e. phenytoin, rifampicin, carbamazepine, barbiturates and St. John’s wort.
d
CYP1A2 inhibitors increase TKI concentration, i.e. ciprofloxacin and fluvoxamine.
e
P-glycoprotein inhibitors increase TKI concentration, i.e. oritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir and
amiodarone.
f
P-glycoprotein inducers decrease TKI concentration, i.e. rifampicin, carbamazepine, phenytoin, phenobarbital and St. John’s wort.
g
P-glycoproteinedependent drugs increase in plasma concentration, i.e. digoxin, colchicine, dabigatran, paclitaxel, pravastatin and vincristine.
h
Breast cancer resistance protein BCRP)edependent drugs increase in plasma concentration, i.e. rosuvastatin, methotrexate, sulfasalazine and topotecan.
i
CYP3A-dependent drugs increase in plasma concentration, i.e. astemizole, cisapride, ciclosporin, ergotamine, fentanyl, pimozide, quinidine, tacrolimus, alfentanil and sirolimus.
j
CYP2C9-dependent drugs increase in plasma concentration, i.e. phenytoin and warfarin.
k
CYP2B6-dependent drugs increase in plasma concentration, i.e. bupropion and efavirenz.
l
CYP2D6-dependent drugs increase in plasma concentration, i.e. metoprolol.
m
QT-prolonging drugs, i.e. amiodarone, kinidine, disopyramide, sotalol, domperidone, methadone, tricyclic antidepressants, antipsychotics, macrolide antibiotics, fluorchinolones, anti-
mycotics, granisetron and ondansetron.
n
CYP3A-dependent drugs decrease in plasma concentration.
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Table 3
Risk factors and preventive measures regarding drug-induced QT prolongation.
Predisposing factors for QT prolongation Risk management
Electrolyte disturbances (hypoK, Mg, Ca) Laboratory monitoring (in vomiting, diarrhoea)
Caution using provoking drugs (i.e. diuretics)
Provoking or interacting drugs Pharmacologic surveillance; drug avoidance
Regular ECGs; screening for gene polymorphisms
Heart failure, left ventricular hypertrophy, extreme bradycardia Cardiologic screening and optimalisation
ECG monitoring
Strenuous physical activity, hypothermia Avoidance, patient education
Hypothyroidism Laboratory screening and suppletion
Female sex, increasing age Awareness
Family history LQT syndrome, sudden death Awareness
Genetic counselling
hypoK, hypokaliemia; Mg, magnesium; Ca, calcium; ECG, electrocardiogram; LQT, long QT.
M. Schiefer et al. / European Journal of Cancer 91 (2018) 92e98 97had progressive disease on full dose osimertinib, we did
not think that a lower dose would give us disease control
or a reassurance about the effect on the QT interval.
2. Conclusion
New drugs have new side-effects that require more
general medical input, often in the course of a busy
oncology clinic. We think that a prolonged QT interval
due to palliative cancer therapy should not automati-
cally result in therapy cessation, but should be weighed
against the risk of disease flare. Genetic testing should
be considered especially with a family history of sudden
death.
We have developed some tables that should help busy
clinicians to make decisions.
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